Research Article

Characterisation of APS-1 Experimental Models Is Crucial for Development of Novel Therapies

Table 4

Q-PCR primer sequence.

cDNAUCSC codePrimer sequenceLocation within cDNASize (bp)

Aireuc007fww.2For 5CAGCAACTCTGGCCTCAAAG 3
Rev 5CTTCGAACTTGTTGGGTGTATAA 3
518-802285
AIREuc062arj.1For 5AGGCAACAGTCCAGGAGGTG 3
Rev 5TAGGGGTTCCCCAGGTGGAC 3
1755-1885131
Ccl1uc007kmu.1For 5GGCTGCCGTGTGGATACAG 3
Rev 5AGGTGATTTTGAACCCACGTTT 3
107-325219
Fabp2uc008rex.2For 5GTGGAAAGTAGACCGGAACGA 3
Rev 5CCATCCTGTGTGATTGTCAGTT 3
359-475117
IL-3uc007ixn.1For 5GGGATACCCACCGTTTAACCA 3
Rev 5AGGTTTACTCTCCGAAAGCTCTT 3
124-262139
Ins2uc009kog.3For 5GCTTCTTCTACACACCCATGTC 3
Rev 5AGCACTGATCTACAATGCCAC 3
231-377147
Spt1uc029svn.1For 5CTGGTGAAAATACTGGCTCTGAA 3
Rev 5AGCAGTGTTGGTATCATCAGTG 3
178-293116
Csnαuc029viy.2For 5ACCTTACTCCCAAAGCTGTCCTTA 3
Rev 5GAGGGTCCAGTCACATCAAATGT 3
870-1005136
Apoa1uc009phb.3For 5 GGCACGTATGGCAGCAAGAT 3
Rev 5 CCAAGGAGGAGGATTCAAACTG 3
182-310129
Fam25cuc007tat.1For 5GAGCAGTTCACGCAGTGGAA 3
Rev 5GCATGGGTAACAGCATCAGTG 3
103-274172
Ctrb1uc009nms.2For 5ATGGCATTCCTTTGGCTTGTG 3
Rev 5GGATAGCATCCTCTCCGTTGAC 3
19-142124
Maoauc009ssa.2For 5GCCCAGTATCACAGGCCAC 3
Rev 5CGGGCTTCCAGAACCAAGA 3
161-277117
Pitpnc1uc011ygq.1For 5CAACCCATCATGTGCTCCTAC 3
Rev 5CCCGAACATCATCCATTGTCAT 3
1310-1484175
Riok2uc008ape.2For 5TAAGCTGTTCAACAATCCCTCC 3
Rev 5GCTGCTTGGTAAACACATTGG 3
1730-1855126
Tmem241uc008ebx.2For 5TCTGCACCTGTTACCTGGCT 3
Rev 5AATGTCTGCCACCCTTGGAAT 3
120-21697
Cnnm2uc008hue.1For 5AAGTGGCCCACCGTGAAAG 3
Rev 5CGCTTCTACTTCTGTTGCTAGG 3
1951-2078128
Cpoxuc007zoa.2For 5ACGGGCGTGTGTTTGAAAAG 3
Rev 5CACAGAACTTACACCCATAGCAG 3
774-925152
MIIt11uc033hxa.1For 5TAAGTAGCCAGTACAGCTCCTT 3
Rev 5CGTAGGTAGGTGTATCTGACAGG 3
14-115102
Ncoa6uc008nkm.2For 5GAATGTGCCCAACTTGTTACAC 3
Rev 5CCCTTCAATCTGAACGGAGAGAA 3
353-536184
Ppibuc009qei.1For 5GGCTCCGTCGTCTTCCTTTT 3
Rev 5ACTCGTCCTACAGATTCATCTCC 3
155-276122
Fezf2uc007sfs.2For 5ACTCGGCCTTGACAGCTGAACG 3
Rev 5TGAGCATTGAACACCTTGCCGCAC 3
1063-1183121
Foxn1uc007kjc.2For 5TTCCATCAGTACTCCCCGGGTGG 3
Rev 5GCGTTGGCCTGGGGTGCAAT 3
831-92595
β-Actinuc009ajk.2For 5GGCTGTATTCCCCTCCATCG 3
Rev 5CCAGTTGGTAACAATGCCATGT 3
193-346154